Promising antileishmanial effectiveness of doxorubicin and Doxil against Leishmania major: An in vitro assay
10.1016/j.apjtm.2016.09.014
- Author:
Azar SHOKRI
1
;
Sajede SADJJADIAN
1
;
Javad AKHTARI
2
;
Masoud KEIGHOBADI
3
;
Azar SHOKRI
4
;
Mahdi FAKHAR
4
;
Saeed Hosseini TESHNIZI
5
;
Saeed EMAMI
6
Author Information
1. Students Research Committee, Department of Parasitology and Mycology, School of Medicine, Mazandaran University of Medical Sciences
2. Immunogenetic Research Center, Department of Physiology and Pharmacology, Faculty of Medicine, Mazandaran University of Medical Sciences
3. Students Research Committee, Department of Medicinal Chemistry and Pharmaceutical Sciences Research Center, Faculty of Pharmacy, Mazandaran University of Medical Sciences
4. Molecular and Cell Biology Research Center, Department of Parasitology and Mycology, School of Medicine, Mazandaran University of Medical Sciences
5. Clinical Research Development Center of Children Hospital, Hormozgan University of Medical Sciences
6. Department of Medicinal Chemistry and Pharmaceutical Sciences Research Center, Faculty of Pharmacy, Mazandaran University of Medical Sciences
- Publication Type:Journal Article
- Keywords:
Doxil;
Doxorubicin;
In vitro;
Leishmania major
- From:
Asian Pacific Journal of Tropical Medicine
2017;10(6):544-548
- CountryChina
- Language:Chinese
-
Abstract:
Objective To evaluate the effect of doxorubicin and its pegylated liposomal formulation (Doxil, Caelyx) on in vitro susceptibility of promastigote and amastigote stages of Leishmania major. Methods Throughout in vitro assays the IC
